Thoracotomy is one of the most painful surgical procedures. Thoracic epidural analgesia (TEA) provides superior pain relief to i.v. opioid. 1 However, despite TEA, some patients still complain of significant discomfort such as shoulder pain or pain related to chest tubes. Adequate postoperative analgesia might improve patient outcome 2 and affect the incidence of chronic postthoracotomy pain. 3 Non-steroidal anti-inflammatory drugs (NSAIDs) are very effective postoperative analgesics. 4 There exist few data concerning the combination of NSAIDs with epidural analgesia after thoracic surgery. 5 The use of perioperative NSAIDs raises the issue of postoperative excessive bleeding. 6 -7 Specific cyclooxygenase-2 (COX-2) inhibitors provide similar postoperative analgesia to non-specific NSAIDs 8 but do not increase the risk of bleeding. 9 However, the potential benefit of COX-2 inhibitor associated with TEA for thoracic surgery has never been investigated. We therefore tested the hypothesis that perioperative celecoxib improves postoperative analgesia provided by TEA after thoracic surgery.
Protocol
Subjects were randomly allocated in two groups (n¼20 in each group). Randomization sequence was predetermined by computer generation. In the celecoxib group, subjects were given 200 mg oral celecoxib (Celebrex w , Pfizer SA, Brussels, Belgium) the evening before surgery, the morning before surgery, and then twice a day for 48 h after operation. In the control group, subjects received placebo tablets at the same time points.
After 6 h n.p.o., all subjects were premedicated with 50 mg hydroxyzine and 0.5 mg alprazolam p.o. 90 min before surgery. In the operating theatre, an i.v. infusion of 10 ml kg 21 After arrival in the post-anaesthesia care unit (PACU), postoperative analgesia was provided to all subjects with a patient-controlled epidural analgesia (PCEA) pump using a combination of ropivacaine 2 mg ml 21 and sufentanil 0.5 mg ml 21 by continuous infusion at 3 ml h 21 , bolus 3 ml, and lockout interval 20 min. PCEA was maintained until the morning of the third postoperative day. Since the aim of the study was to investigate the effect of celecoxib on epidural analgesia, only subjects with effective epidural analgesia assessed using thermosensory testing in the PACU were included in the study. In addition, all subjects were given 2 g propacetamol i.v., a precursor of acetaminophen (Pro-dafalgan w , UPSAMEDICA Brussels, Belgium; 2 g propacetamol¼1 g acetaminophen) every 6 h. In the case of inadequate analgesia [pain scores at rest .30 on a 100 mm visual analogue scale (VAS)], 100 mg tramadol i.v. (Contramal w Grü nenthal, Woluwe-Saint-Etienne, Belgium) was given as rescue medication every 6 h.
Measurements
Pain scores at rest and during coughing and mobilization (moving from the lying to the sitting position) were measured on a 100 mm VAS on admission to the PACU, 4 h after surgery and three times a day on postoperative days 1 and 2. Subject satisfaction with postoperative analgesia was assessed on a 100 mm VAS at the end of the second postoperative day (0, totally dissatisfied; 100, totally satisfied). Epidural local anaesthetic consumption was also recorded.
Bleeding through chest tubes was measured, and blood haemoglobin and plasma, urea, creatinine and troponin-T concentrations were assayed after operation. The incidence of postoperative nausea and vomiting and urinary retention were also recorded.
Pulmonary function [forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow rate] was tested before operation and twice a day during the first three postoperative days after chest physiotherapy using a portable spirometer (Spirobank w , MIR, Rome, Italy). Selected postoperative complications were prospectively noted: fever (core temperature .388C), pneumonia diagnosed clinically and by culture and chest radiography, myocardial ischaemia defined as a change in the ECG with an elevation of troponin-T above 0.03 mg litre 21 , supraventricular arrhythmia, bleeding through chest tubes, need for homologous transfusion, and renal insufficiency defined as an increase in plasma creatinine concentration .20% of baseline.
Statistical analysis
Data are expressed as mean (SD). Student's t-test, ANOVA for repeated measures, or the Mann-Whitney test was used for quantitative data. Fischer exact test was used to compare qualitative data (SPSS for Windows 12.0). A value of P,0.05 was considered significant. The results of a pilot study in our institution indicated that 17 subjects per group allowed detection of a 20 mm reduction in VAS pain score during coughing assessed on the morning of the first postoperative day with a¼0.05 and a 80% power.
Results
Two subjects in each group were excluded because of early unintentional removal of epidural catheter. Data from 36 subjects were used for analysis. Subject characteristics and types of surgery were similar in the two groups ( Table 1) . The consumption of the ropivacaine/sufentanil mixture and the need for rescue medication (tramadol) were not significantly different between the two groups ( Table 2) . Pain scores were significantly lower at rest (P¼0.026) and on coughing (P¼0.021) in the celecoxib group when compared with the control group (Fig. 1A and B) . Pain scores during mobilization were also less in the celecoxib group but the Effect of celecoxib on pain after thoracotomy difference was not statistically significant (P¼0.19) (Fig. 1C) . Satisfaction with postoperative analgesia was significantly (P¼0.0033) greater at postoperative day 2 in the celecoxib group (Table 2) . No difference was observed in the incidence of postoperative nausea and vomiting or urinary retention. FVC and FEV1 significantly deteriorated after surgery, but the reductions in these lung volumes were comparable in the two groups. Peak expiratory flow rate or the ratio between FEV1 and FVC did not differ significantly between the groups after surgery (Table 3) .
No patient had postoperative elevation of plasma troponin-T. No difference in postoperative morbidity was observed between the two groups ( Table 3) .
Discussion
This study suggests that perioperative treatment with celecoxib, a selective COX-2 inhibitor, significantly improves postoperative analgesia provided by a thoracic PCEA after thoracotomy for lung resection. As a consequence, patient satisfaction with postoperative analgesia was also greater. Postoperative pulmonary function and morbidity were not affected by treatment with celecoxib. We consider the reduction in pain scores by celecoxib (.15 mm on a 100 mm VAS at several time points) as clinically relevant since pain scores were already low with epidural analgesia in the control group, and it resulted in an improved patient satisfaction.
NSAIDs improve analgesia obtained with i.v. opioids after cardiothoracic surgery. 10 Studies on the potential benefit of NSAIDs combined with epidural analgesia for thoracic surgery are rare. In a previous study, Bigler and colleagues 5 used continuous epidural infusion of bupivacaine with morphine for analgesia after thoracotomy, which resulted in almost no pain in the control group, making it difficult to demonstrate any additional effect of the NSAID piroxicam.
Although the analgesic and anti-inflammatory effects of NSAIDs are mediated by the inhibition of COX enzymes, NSAIDs ability to block COX-1 and COX-2 and to produce analgesia and anti-inflammatory effects differs. 11 In fact, piroxicam seems to be more anti-inflammatory than analgesic. 11 Moreover, NSAID administration in the study of Bigler and colleagues was started just before surgery. We initiated celecoxib treatment the day before surgery, which allowed more time for drug distribution to the spinal cord where COX-2 activation contributes to nociception and hyperalgesia after tissue trauma. Nevertheless, the efficiency of preemptive analgesia with NSAIDs remains controversial. 12 13 Our results are similar to those of a study investigating the effect of rofecoxib, a selective COX-2 inhibitor no longer available, on postoperative epidural analgesia after knee replacement surgery in which rofecoxib was begun 24 h before surgery. Blood transfusion (n) 0 0
Urea .20% (n) 4 3
Creatinine .20% (n) 1 1
Pulmonary infection (n) 0 2
Fever .388C (n) 0 2
Ropivacaine -sufentanil epidural solution consumption at 48 h (ml)
268 (84) 282 (78) Total tramadol consumption at 48 h (mg)
194 (147) Despite better analgesia, postoperative pulmonary dysfunction is not improved in patients treated with celecoxib. This confirms that pain is not the main determinant of the postoperative pulmonary restrictive syndrome. Complete pain relief obtained with epidural opioids alone fails to reverse this restrictive syndrome; the most effective treatment to reduce the dysfunction is epidural local anaesthetic. 2 In our study, both groups received epidural ropivacaine at similar doses, so it is not surprising that postoperative pulmonary dysfunction was also similar in both groups. Contrary to non-selective NSAIDs, COX-2 inhibitors do not increase the risk of bleeding. In this study, pleural bleeding and the postoperative drop in haemoglobin concentration were comparable in the two groups. All NSAIDs can exacerbate the development of renal failure. 17 In our study, the number of subjects with a postoperative increase in urea and creatinine plasma concentrations was comparable in the two groups. However, our study was not powered to exclude effects on postoperative bleeding and renal function. Studies have shown a significant increase in coronary acute ischaemic events in patients receiving long-term COX-2 inhibitor treatment. 18 -19 In cardiac surgery patients, the incidence of ischaemic events increased with prolonged postoperative use of parecoxib. 20 However, in patients undergoing major non-cardiac surgery, 10 days of perioperative administration of valdecoxib-parecoxib did not increase the incidence of major cardiovascular postoperative events compared with placebo. 21 In our study, administration of celecoxib for 3 days did not result in any ischaemic cardiac events, but it was not powered to test this. The lack of cardiac ischaemic events may be due to the small sample size, the short duration of COX-2 inhibitor administration, and patients' selection. Indeed, our patients are less likely to have atherosclerotic disease than cardiac surgery patients.
In conclusion, 200 mg celecoxib started the evening before surgery and given twice a day for 48 h after surgery significantly improved the analgesia provided by TEA after thoracotomy with no drug-induced side-effects detected.
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